Manager/Senior Manager, Clinical Innovation and Corporate Communications
- Salary
- $108K–$185K
- Hiring from
- United States
- Work type
- Hybrid
- Posted
626,551 remote jobs, straight from company career pages
100% free · New jobs every minute
Show job descriptionHide job description
Role Summary
Lexeo is seeking a Manager or Senior Manager, Clinical Innovation and Corporate Communications, to help advance our clinical trial innovation strategy, develop clinically-oriented corporate communications across our pipeline, and support broader corporate strategy and commercial development projects.
This highly cross-functional role will evaluate new geographies, trial models, and other approaches that could improve the speed, efficiency, and execution of clinical development across Lexeo’s portfolio. The individual will also translate complex clinical, scientific, and regulatory information into clear, compelling communications for patients, healthcare professionals, media, investors, and other external audiences.
This role will sit within the Clinical organization and partner closely with Medical Affairs, Patient Affairs, Investor Relations, and other functions. A successful candidate will combine strategic thinking with hands-on execution and will have the opportunity to shape high-priority initiatives across clinical development, communications, and corporate strategy.
We welcome applications from candidates located across the Northeast and Mid-Atlantic.
Primary Responsibilities
Corporate Communications
Portfolio & Corporate Strategy Support
Required Skills and Qualifications
About LEXEO
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Our work culture is a hybrid model with 2 days in the New York City office and 3 days working from home.
LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.